Efectos de Múltiples Dosis de Itraconazol y MK-2828 en la Farmacocinética de Dosis Única en Participantes Sanos

MK-2828

Itraconazole

MK-2828

Midazolam

Part 1 (Itraconazole): Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-2828

Part 1 (Itraconazole): Maximum Plasma Concentration (Cmax) of MK-2828

Part 2 (Midazolam): Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Midazolam

Part 2 (Midazolam): Maximum Plasma Concentration (Cmax) of Midazolam

Part 1 (Itraconazole): Number of Participants Experiencing an Adverse Event (AE)

Part 1 (Itraconazole): Area Under the Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-2828

Part 1 (Itraconazole): Area Under the Curve From Time 0 to 24 Hours (AUC0-24hrs) of MK-2828

Part 1 (Itraconazole): Time to Maximum Plasma Concentration (Tmax) of MK-2828

Part 1 (Itraconazole): Apparent Terminal Half-life (t1/2) of MK-2828

Part 1 (Itraconazole): Apparent Clearance (CL/F) of MK-2828

Part 1 (Itraconazole): Plasma Concentration at 24 Hours (C24) of MK-2828

Part 1 (Itraconazole): Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-2828

Part 1 (Itraconazole): Number of Participants Who Discontinue Study Treatment Due to an AE

Part 2 (Midazolam): Area Under the Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of Midazolam

Part 2 (Midazolam): Area Under the Curve From Time 0 to 24 Hours (AUC0-24hrs) of Midazolam

Part 2 (Midazolam): Time to Maximum Plasma Concentration (Tmax) of Midazolam

Part 2 (Midazolam): Apparent Terminal Half-life (t1/2) of Midazolam

Part 2 (Midazolam): Apparent Clearance (CL/F) of Midazolam

Part 2 (Midazolam): Plasma Concentration at 24 Hours (C24) of Midazolam

Part 2 (Midazolam): Apparent Volume of Distribution During Terminal Phase (Vz/F) of Midazolam

Part 2 (Midazolam): Number of Participants Experiencing an adverse event (AE)

Part 2 (Midazolam): Number of Participants Who Discontinue Study Treatment Due to an AE